The Trump Administration’s Executive Order on drug pricing is set to reshape the pharmaceutical landscape, with sweeping implications for pricing transparency, global competition, and supply chain resilience. From Most Favored Nation pricing to operational agility, this guide outlines five critical actions to protect margins, ensure compliance, and stay competitive in a rapidly evolving market.
Stephen Ottley, Maine Pointe Managing Director and Head of Pharmaceuticals & Chemicals, breaks down the key elements, potential industry impacts, and—most importantly—what pharmaceutical companies can do now to prepare. Those that wait run potential risk of losing a significant portion of their American market share, losing pricing-related business from American insurance companies, and miss a golden opportunity to cash in speed to market with generic replacements, among other risks.